Total
0
Shares
Founder and CEO, Iris Bincovich
Source: The Investor Coliseum

Subscribe

Be the first with the news that moves the market
  • InnoCan Pharma's (INNO) Liposome Platform Technology has achieved a 7-week release of CBD into the bloodstream in a recent animal study
  • The company is encouraged by the result given that CBD only stays in the bloodstream for 24 hours when administered through traditional channels
  • Liposome Platform Technology may have use cases for epilepsy, pain relief, inflammation and central nervous system disorders
  • InnoCan Pharma is a pharmaceutical tech company focused on the development of drug delivery platforms containing CBD
  • InnoCan Pharma (INNO) is trading flat at $0.50 per share

InnoCan Pharma's (INNO) Liposome Platform Technology has achieved a 7-week release of CBD into the bloodstream in a recent animal study.

The mice in question demonstrated the prolonged release of cannabidiol (CBD) following two local injections.

InnoCan believes the result is encouraging given the 24-hour CBD presence in the bloodstream when administered through traditional channels.

Dr. Ahuva Cern - a senior researcher in the lab of Professor Chezy Berenholz - led the study based on InnoCan's licensed Liposome Platform Technology for injectable CBD solutions.

The company is involved in a worldwide exclusive research and license agreement with Yissum Research and Development Company, the commercial arm of The Hebrew University of Jerusalem, with the goal of designing, preparing, characterizing and evaluating hydrogels containing CBD (or other cannabinoid) loaded liposomes.

InnoCan's Liposome Platform Technology may have a wide range of applications, such as epilepsy, pain relief, inflammation and central nervous system disorders.

"We are extremely satisfied with the initial results of this study which shows significant improvement in administrating CBD through InnoCan's LPT," said Professor Berenholz. "Finding remaining CBD in the injection site could indicate even a longer prolonged release of CBD into the bloodstream."

Iris Bincovich, InnoCan's CEO, added,

"This study marks another positive and exciting result in our ongoing injectable-CBD research. These results may open the door to a wide range of exciting therapeutic possibilities, especially in treatment of conditions related to the central nervous system."

InnoCan Pharma is a pharmaceutical tech company focused on the development of drug delivery platforms containing CBD.

InnoCan Pharma (INNO) is trading flat at $0.50 per share as of 9:42 am ET.

More From The Market Herald

" Wellteq (CSE:WTEQ) collaborates with Garmin to counter COVID-19

Wellteq (WTEQ) is collaborating with Garmin to offer new enterprise wellness solutions in the Asia Pacific region in response to recent COVID-19 surges.

" ScreenPro (CSE:SCRN) completed over 19,000 COVID-19 tests in May

ScreenPro (SCRN) completed over 19,000 tests for production companies in Toronto and Vancouver in May.

" Nextleaf (CSE:OILS) awarded U.S. Patent and engages CannDelta for psychedelics dealer’s licence

Nextleaf Solutions (OILS) has received approval for a patent pertaining to the extraction and purification of THC and CBD.

" Medicenna (TSX:MDNA) submits clinical trial application for a Phase 1/2 study of MDNA11

Medicenna Therapeutics Corp. (MDNA) has submitted a clinical trial application to initiate a Phase 1/2 clinical study of MDNA11